LABT (Lakewood-Amedex Biotherapeutics) Total Liabilities: $3.04 Mil (As of Mar. 2026)


LABT Lakewood-Amedex Biotherapeutics Inc LABT
8 GF Score
Price $3.55
View Full Analysis

What is Lakewood-Amedex Biotherapeutics Total Liabilities?

Lakewood-Amedex Biotherapeutics LABT +2.33% 8 Total Liabilities is $3.04 Mil as of Mar. 2026. GuruFocus rates LABT with a GF Score™ of 8/100.

Lakewood-Amedex Biotherapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $3.04 Mil.

Lakewood-Amedex Biotherapeutics's quarterly Total Liabilities increased from Sep. 2025 ($2.25 Mil) to Dec. 2025 ($2.45 Mil) and increased from Dec. 2025 ($2.45 Mil) to Mar. 2026 ($3.04 Mil).

Lakewood-Amedex Biotherapeutics's annual Total Liabilities declined from Dec. 2023 ($2.34 Mil) to Dec. 2024 ($0.66 Mil) but then increased from Dec. 2024 ($0.66 Mil) to Dec. 2025 ($2.45 Mil).

Lakewood-Amedex Biotherapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Lakewood-Amedex Biotherapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakewood-Amedex Biotherapeutics Total Liabilities Chart

Lakewood-Amedex Biotherapeutics Annual Data
Trend Dec23 Dec24 Dec25
Total Liabilities
2.34 0.66 2.45

Lakewood-Amedex Biotherapeutics Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial 0.66 0.00 2.25 2.45 3.04
LABT
8GF Score
Lakewood-Amedex Biotherapeutics Inc LABT
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakewood-Amedex Biotherapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Lakewood-Amedex Biotherapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.405+(0.041+3.6776137690708E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.45

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=0.482--1.965
=2.45

Lakewood-Amedex Biotherapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.028+(0.01+-2.1337098754515E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=3.04

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=0.196--2.842
=3.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $3.04 Mil mean?
Lakewood-Amedex Biotherapeutics (LABT) has a Total Liabilities of $3.04 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Lakewood-Amedex Biotherapeutics and its competitors.
Is Lakewood-Amedex Biotherapeutics' Total Liabilities too high?
Lakewood-Amedex Biotherapeutics' current Total Liabilities is $3.04 Mil. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' Total Liabilities compare to CURX and PBM?
Lakewood-Amedex Biotherapeutics' Total Liabilities of $3.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Lakewood-Amedex Biotherapeutics and its competitors. Lakewood-Amedex Biotherapeutics's current Total Liabilities is $3.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current Total Liabilities of $3.04 Mil. The current Total Liabilities is $3.04 Mil. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current Total Liabilities is $3.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lakewood-Amedex Biotherapeutics Business Description

Address 8031 Cooper Creek Blvd, Unit 103, University Park, FL, USA, 34201
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score

Get the complete analysis for LABT

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price